Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
C1QTNF9 Biologics Sequence Review Report 2026: Complement C1q and tumor necrosis factor-related protein 9A Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of C1QTNF9 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
C1QTNF6 Biologics Sequence Review Report 2026: Complement C1q tumor necrosis factor-related protein 6 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of C1QTNF6 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
C1QTNF8 Biologics Sequence Review Report 2026: Complement C1q tumor necrosis factor-related protein 8 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of C1QTNF8 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
C1QTNF4 Biologics Sequence Review Report 2026: Complement C1q tumor necrosis factor-related protein 4 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of C1QTNF4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
C1QTNF2 Biologics Sequence Review Report 2026: Complement C1q tumor necrosis factor-related protein 2 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of C1QTNF2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
C1QTNF5 Biologics Sequence Review Report 2026: Complement C1q tumor necrosis factor-related protein 5 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of C1QTNF5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
C1QTNF3 Biologics Sequence Review Report 2026: Complement C1q tumor necrosis factor-related protein 3 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of C1QTNF3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
C1QTNF1 Biologics Sequence Review Report 2026: Complement C1q tumor necrosis factor-related protein 1 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of C1QTNF1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
ADGRE4P Biologics Sequence Review Report 2026: Putative adhesion G protein-coupled receptor E4P Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of ADGRE4P protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
ADGRG3 Biologics Sequence Review Report 2026: Adhesion G protein-coupled receptor G3 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of ADGRG3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
ADGRG5 Biologics Sequence Review Report 2026: Adhesion G protein-coupled receptor G5 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of ADGRG5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
ACKR4 Biologics Sequence Review Report 2026: Atypical chemokine receptor 4 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of ACKR4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.